2010
- Planned the Celebration 40 Years of Excellence (1970 - 2010)
- Developed and introduced new Test Kits: Renin (active), Amyloid beta Auto-Ab (Serum),
L1-CAM, CRYPTO-1, Afamin
2009
- Introduced the world to the first Hepcidin Test Kit
- Developed a Connective Tissue Growth Factor (CTGF) Elisa which allows for clinical-value measurement in serum of CTGF in patients with chronic Hepatitis C Virus (HCV) and chronic liver disease
- Added Vitamin Assays to the DRG product line
- Presented the new and unique closed system DRG:HYBRiD.XL at MEDICA 2009 in Duesseldorf -
a fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry
2008
- Received two U.S. patents for its Hepcidin Test Kit
- Began the development of a closed system, our DRG:HYBRiD.XL, a fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry.
- Gained U.S. FDA approval for DRG's 17α-OH Progesterone Saliva kit (SLV-3140) for use worldwide
- Developed a new Preeclampsia Test (PLGF ELISA) to determine the occurrence of preeclampsia in pregnant women. Preeclampsia, a multi-systemic disorder affecting mother and child at the end of the second trimester, is a major cause of maternal and perinatal mortality worldwide
2007
- Launched a new CHROMagar medium targeted to detect the Vancomycin Resistant Enterococcus faecalis and faecium and to differentiate them from the other bacteria
- Announced its newest line of Veterinary ELISAs, including Canine, Equine, Rat and Lab animals
- Introduced a new Avian Influenza A ELISA Kit
2006
- Introduced the Neonatal Screening PKU (Phenylketonuria). PKU is one of the most prevalent hereditary diseases in the metabolism of amino acids
- Launched the new ELISA PAPP-A
2005
- DRG launched its Platinum Standard Tumor Markers
2004
- Developed TUMOR MARKERS, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra 21-1
- Introduced the Corticosterone & Estrone ELISAs
2003
- Developed and introduced the world to the first Assay for measurement of Hepcidin
- Acquired Novum-Diagnostics, Dietzenbach, and took over the production of more than 70 ELISAs for infectious diseases in DRG-Novum Branch lab
2002
- Developed and introduced various Saliva kits including DHEA Saliva
2001
- Dade Behring Technology transferred to DRG production of C5a and PAP - ELISAs
2000
- Developed and introduced the IGF1, IL-6, Cortisol- Saliva, Androstenedione ELISAs
- Certification of QM-System EN ISO 9001: 1994 DNV
1999
- Developed and introduced Insulin, PAPP-A, TGFß II ELISAs
1998
- Moved to DRG New Building Marburg, Germany
- 25 years DRG Instruments GmbH, Marburg, Germany
|
|
1997
- Developed and introduced Leptin, TGFß, and ß-HCG ELISAs
1996
- Developed and introduced Free Estriol ELISA
1995
- Developed and introduced the first worldwide non-radioactive C-Peptide and Proinsulin Assays
1994
- Developed and Introduced DHEA-S, Progesterone, Testosterone, PMSG, ß-HCG ELISAs
- DRG Diagnostics Branch Office Berlin, Germany
1993
- DRG Techsystems founded in Moscow, Russia
- Developed and introduced 17-OH-Progesterone ELISA
1992
- DRG Spol. s.r.o., founded in Brno, Czechoslovakia (Czech Republic)
- Developed and Introduced AFP, HCG, FSH, Prolactin and LH
1991
- DRG Biomed founded in St. Petersburg, Russia
- Market entry of first Neonatal DRG Elisa: HPL
1990
- DRG MEDTEK founded in Warsaw, Poland
- Started R&D and production of Elisa diagnostics in Marburg, Germany
1988
- DRG AG Zurich Switzerland
1985
- Began in-house R&D Operations
1982
- West and East Europe Expansion
1981
- Entered Middle East Markets: Saudi Arabia, Kuwait and Iran
- St. Jude Medical Bi-Leaflet Mechanical Heart Valve introduced to European Cardiac Surgery Market by DRG International
1975
- First participation at MEDICA, Düsseldorf, Germany
1974
- DRG Instruments GmbH moved to Marburg, Germany
1973
- Distribution of RIA's in Germany
- DRG Instruments GmbH, Germany, founded in Munich
1970
- DRG enters market in Europe, USSR, Poland, Yugoslavia
- DRG International Inc. (NJ) founded by Dr. C.E. Geacintov
|
